Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says

Executive Summary

Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency

You may also be interested in...



PhRMA Wary Of Large Simple Safety Trials, Tells FDA Not To Create Phase III+

Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9

FDA Drug Safety Rule Would Promote Premarketing Adverse Event Reports

FDA's proposed definition of "suspected adverse drug reactions" would encourage more premarketing adverse event reporting

Greenwood/DeGette Human Subject Protection Bill Has Support Of ACRO

HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel